News
MyChesCo on MSN26m
ArriVent BioPharma Eyes Early 2026 for Phase 3 Lung Cancer Drug DataArriVent BioPharma, Inc. (Nasdaq: AVBP) announced it expects topline data in early 2026 from its global Phase 3 FURVENT trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback